Monitoring of Active Human Herpes Virus 6 Infection in Iranian Patients with Different Subtypes of Multiple Sclerosis

Table 2

Prevalence of HHV-6-DNA (copies/mL) and HHV-6-antibodies (U/mL) among different subtypes of MS. HHV-6-DNA was analyzed in serum via qPCR as described previously. Concentration of plasma anti-HHV-6, IgG and IgM were measurement in an automated instrument, according to the manufacturer’s instructions. Data are representative of three independent experiments.

	Saliva	Serum	PBMCs	CSF	Anti-IgG	Anti-IgM
			P (%)
			[mean ± SD]
MS (𝑛=78)
(1) RRMS (𝑛=46); CSF (𝑛=22)	6 (13.04); [127±12.43]	35 (76.08); [272±39.15]	36 (78.26); [178±42.60]	10 (45.45); [128±7.58]	38 (82.60); [15.96±1.43]	22 (47.82); [24.85±1.92]
(2) SPMS (𝑛=11); CSF (𝑛=6)	3 (27.27); [128±9.84]	7 (63.63); [294±44.77]	7 (63.63); [151±14.44]	1 (16.66); [145]	11 (100); [16.51±2.27]	4 (36.36); [25.67±1.43]
(3) PPMS (𝑛=21); CSF (𝑛=10)	0 (—); [---]	5 (23.80); [165±12.45]	9 (42.85); [125±7.23]	0 (—); [---]	12 (57.14); [13.32±1.17]	1 (4.76); [23.05]
Sig. (2-tailed)
Subtypes (1), (2)	NS	NS	𝑃<0.05	NS	NS	NS
Subtypes (1), (3)	—	𝑃<0.001	𝑃<0.001	—	𝑃<0.001	NS
Subtypes (2), (3)	—	𝑃<0.001	𝑃<0.001	—	𝑃<0.001	NS

PBMCs: peripheral blood mononuclear cells; CSF: cerebrospinal fluid; PPMS: primary progressive MS; RRMS: relapsing-remitting MS; SPMS: secondary progressive MS; P: positive; NS: not significant.